Basal insulin

Basal insulin has been studied in 28 papers since 2016: 2 trials and 10 observational studies in people, 15 reviews; 6 in the past year. The newest story, Oct 29, 2026: “Drug–dementia link in type 2 diabetes with mild cognitive impairment”.

Intervention

28 papers study it4 findingsUpdated

2 new papers in 30 daysSee all 28 papers on basal insulin

At a glance

Independent labs found the same change in people. 3 independent labs in 2 countries; 8 trials, none about aging, 3 with no results posted.

“insulin caused less gastrointestinal events (93.5%)”
Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A bayesian network meta-analysisFrontiers in pharmacology2022doi:10.3389/fphar.2022.998816

None of its findings points the other way.

Humans: replicated by independent labs. Cells, worms or flies and mice: nothing yet.
  • 3 independent labs in 2 countries
  • 8 trials, none about aging, 3 with no results posted
  • Funders: Abbott and 7 more
  • 1 of 4 findings with company ties
  • 1 of 8 trials sponsored by its developers
  • Human trial2
  • Humans10
  • In silico1

Studies in people

1 study gave basal insulin to people and measured what changed.

What changedDesignPeopleSource

down: Decreases gastrointestinal adverse eventsSCURA probability 93.5%

Review of trials7,245 people pooledPatient cohortsFrontiers in pharmacology, Oct 14, 2022

What did studies of basal insulin find?

3

Studies of basal insulin measured 3 outcomes: HbA1c, body weight and gastrointestinal adverse events.

HbA1c

downin humans2

2 studies
  1. Basal insulin is linked with lower HbA1c in humans (severely uncontrolled type 2 diabetes).

    Humansseverely uncontrolled type 2 diabetes

  2. Basal insulin is linked with lower HbA1c in humans (added to metformin after initial metformin monotherapy failure).

    Humansadded to metformin after initial metformin monotherapy failure1 yearn = 16,681

More on HbA1c

Body weight

no changein humans1

1 study
  1. Basal insulin was not clearly linked with body weight in humans (compared with baseline in severely uncontrolled type 2 diabetes).

    Humanscompared with baseline in severely uncontrolled type 2 diabetes

Gastrointestinal adverse events

downin humans1

1 study
  1. Basal insulin decreases gastrointestinal adverse events in humans (compared with tirzepatide and GLP-1 receptor agonists in network meta-analysis) (SCURA probability 93.5%).

    Human trialcompared with tirzepatide and GLP-1 receptor agonists in network meta-analysis

Has basal insulin been tested in people?

0 of 8 about aging

Yes: 2 trials and 10 observational studies in people have been published, and 8 trials are registered.

In trials

Who is developing basal insulin?

1 company: DexCom.

Companies

Trial sponsors

Latest

Dec 2025: 0Jan 2026: 1Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 1Jul 2026: 1Aug 2026: 0Sep 2026: 2Oct 2026: 1Nov 2026: 06 papers in 12 months
Alzheimer's & Dementia

Drug–dementia link in type 2 diabetes with mild cognitive impairment

In adults with type 2 diabetes and mild cognitive impairment, estimated dementia rates over a mean 3.9 years were 15.5% for one drug class versus 20.4% for another.In adults with type 2 diabetes and mild cognitive impairment, estimated dementia rates over a mean 3.9 years were 15.5% for one drug class versus 20.4% for another.

Cohort · 1,320 peopleMild cognitive impairment

See all 28 papers on basal insulin